Journal
DERMATOLOGY AND THERAPY
Volume 12, Issue 11, Pages 2415-2452Publisher
ADIS INT LTD
DOI: 10.1007/s13555-022-00818-7
Keywords
Contact immunotherapy; Dinitrochlorobenzene; DNCB; Diphencyprone; Diphenylcyclopropenone; DPCP; Squaric acid dibutylester; SADBE
Categories
Ask authors/readers for more resources
Contact immunotherapy plays a significant role in the treatment of skin diseases, including extensive alopecia areata, melanoma, infectious, neoplastic, and inflammatory conditions. This review summarizes the current evidence and discusses the mechanism, prognosis prediction, efficacy, and safety of contact immunotherapy.
For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available